Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Herter-Sprie, Grit S., Buczkowski, Kevin A., Richards, William G., Gandhi, Leena, Redig, Amanda J., Rodig, Scott J., Asahina, Hajime, Jones, Robert E., Kulkarni, Meghana M., Kuraguchi, Mari, Palakurthi, Sangeetha, Fecci, Peter E., Johnson, Bruce E., Janne, Pasi A., Engelman, Jeffrey A., Gangadharan, Sidharta P., Costa, Daniel B., Freeman, Gordon J., Bueno, Raphael, Hodi, F. Stephen, Dranoff, Glenn, Wong, Kwok-Kin, Hammerman, Peter S.·2016·Nature Communications

DOI 10.1038/ncomms10501

Cited by (1,000)

Items 701–800 of 1,000

Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies
Nicolas Roussot, Courèche Kaderbhaï, François Ghiringhelli · 2025 · Cancers
Cancer metastasis: molecular mechanisms and therapeutic interventions
Xiaofeng Dai, Ming Xi, Jitian Li · 2025 · Molecular Biomedicine
Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis
Qiqing Sun, Yiyin Zhang, Mengqi Liu, Ye Zeng, Xianjun Yu, Xiaowu Xu, Yi Qin · 2019 · Cancer Cell International
Increased Tim-3 expression on TILs during treatment with the Anchored GM-CSF vaccine and anti-PD-1 antibodies is inversely correlated with response in prostate cancer
Xinji Zhang, Haixiong Chen, Guanfeng Li, Xiangyun Zhou, Yuqiang Shi, Feng Zou, Yuanxiang Chen, Jimin Gao, Shaomin Yang, Shihao Wu et al. · 2019 · Journal of Cancer
Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review
Wu-Yan Xia, Wen Feng, Chenchen Zhang, Yujia Shen, Qin Zhang, Wen Juan Yu, Xu‐Wei Cai, Xiaolong Fu · 2020 · Translational Lung Cancer Research
TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy with Activation
Tram N. Dao, Sagar M. Utturkar, Nadia A. Lanman, Sandro Matosevic · 2020 · Cancers
TAM kinase inhibition and immune checkpoint blockade– a winning combination in cancer treatment?
Pavlos Msaouel, Giannicola Genovese, Jianjun Gao, Suvajit Sen, Nizar M. Tannir · 2020 · Expert Opinion on Therapeutic Targets
Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
Rachel L. Y. Ho, Ivy A. W. Ho · 2021 · Cancers
Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity
Huey-Jen L. Lin, Yingguang Liu, Denene Lofland, Jiayuh Lin · 2022 · Cancers
Emerging roles of ferroptosis in glioma
Jiaqi Shi, Ning Yang, Mingzhi Han, Chen Qiu · 2022 · Frontiers in Oncology
Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
Akira Ooki, Hiroki Osumi, Keisho Chìn, Masayuki Watanabe, Kensei Yamaguchi · 2023 · Therapeutic Advances in Medical Oncology
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance
Filippo Pelizzaro, Fabio Farinati, Franco Trevisani · 2023 · Biomedicines
Increased TIM3+CD8+T cells in Myelodysplastic Syndrome patients displayed less perforin and granzyme B secretion and higher CD95 expression
Jinglian Tao, Lijuan Li, Yingshuai Wang, Rong Fu, Huaquan Wang, Zonghong Shao · 2016 · Leukemia Research
Molecular genetic and immunotherapeutic targets in metastatic melanoma
Céline Melis, Aljosja Rogiers, Oliver Edgar Bechter, Joost J. van den Oord · 2017 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions
Young Kwang Chae, Michael S. Oh, Francis Joseph Giles · 2017 · The Oncologist
Genomic Testing in Lung Cancer: Past, Present, and Future
Céline Mascaux, Ming‐Sound Tsao, Fred R. Hirsch · 2018 · Journal of the National Comprehensive Cancer Network
Anti-PD-1 And Anti-PD-L1 Antibodies as Immunotherapy Against Cancer: A Structural Perspective
Luis Córdova-Bahena, Marco Antonio Velasco-Velázquez · 2020 · Revista de investigaci�n Cl�nica
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
Francesco Passiglia, Maria Lucia Reale, Valeria Cetoretta, Silvia Novello · 2021 · ImmunoTargets and Therapy
Neuroinflammation in Autoimmune Disease and Primary Brain Tumors: The Quest for Striking the Right Balance
Dana K. Mitchell, Jack M. Shireman, Elizabeth A. Sierra Potchanant, Montserrat A. Lara-Velazquez, Mahua Dey · 2021 · Frontiers in Cellular Neuroscience
Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics
Dhaneshree Bestinee Naidoo, Anil Amichund Chuturgoon · 2021 · International Journal of Molecular Sciences
Inhibition of Melanoma Cell–Intrinsic Tim-3 Stimulates MAPK-Dependent Tumorigenesis
Tobias Schatton, Yuta Itoh, Christina P. Martins, Erik Rasbach, Praveen Kumar Singh, Mariana Silva, Kyla Mucciarone, Markus Vincent Heppt, Jenna Geddes-Sweeney, Kate Stewart et al. · 2022 · Cancer Research
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
Marina Natoli, Klas Hatje, Pratiksha Gulati, Fabian Junker, Petra Herzig, Zhiwen Jiang, Iakov I. Davydov, Markus Germann, Marta Trüb, Daniel Marbach et al. · 2022 · Journal for ImmunoTherapy of Cancer
Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies
Piero Giuseppe Meliante, Christian Barbato, Federica Zoccali, Massimo Ralli, Antonio Greco, Marco DE VINCENTIIS, Andrea Colizza, Carla Petrella, Giampiero Ferraguti, Antonio Minni et al. · 2022 · International Journal of Molecular Sciences
Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma
Binghao Zhao, Jiaming Wu, Huanzhang Li, Yuekun Wang, Yaning Wang, Hao Xing, Yu Wang, Wenbin Ma · 2023 · Cell Communication and Signaling
The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors
Andrew S. Luksik, Russell Maxwell, Tomás Garzón-Muvdi, Michael K. Lim · 2017 · Neurotherapeutics
Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model
Mikołaj Kocikowski, Katarzyna Dziubek, Maciej Parys · 2020 · Cancers
Immunotherapeutic strategies beyond the PD-1/PD-L1 pathway in head and neck squamous cell carcinoma – A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA
Ann‐Kristin Struckmeier, Martin Gosau, Ralf Smeets · 2024 · Oral Oncology
IFN Signaling and ICB Resistance: Time is on Tumor’s Side
Alejandro López‐Soto, Segundo R. Gonzalez, Alicia R. Folgueras · 2017 · Trends in cancer
Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer
Liliang Xia, Hui Wang, Mingjiao Sun, Yi Yang, Chengcheng Yao, Sheng He, Huangqi Duan, Weimin Xia, Ruiming Sun, Yaxian Yao et al. · 2021 · Science China Life Sciences
Functionally Competent, PD-1+ CD8+ Trm Cells Populate the Brain Following Local Antigen Encounter
Amalie Skak Schøller, Loulieta Nazerai, Jan Pravsgaard Christensen, Allan Randrup Thomsen · 2021 · Frontiers in Immunology
Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy
Benedetta Apollonio, Nikolaos Ioannou, Despoina Papazoglou, Alan G. Ramsay · 2021 · Frontiers in Oncology
Tumor immunotherapy: Mechanisms and clinical applications
Cheng Nong, Pengbo Guan, Li Li, Huiyuan Zhang, Hongbo Hu · 2022 · MedComm – Oncology
Unravelling T cell exhaustion through co‐inhibitory receptors and its transformative role in cancer immunotherapy
Simin Xiang, Sen Li, Junfen Xu · 2025 · Clinical and Translational Medicine
Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion
Alessandro Ascione, Claudia Arenaccio, Alessandra Mallano, Michela Flego, Mara Gellini, Mauro Andreotti, Craig W. Fenwick, Giuseppe Pantaleo, Stefano Vella, Maurizio Federico · 2019 · BMC Biotechnology
Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity?
Nicola Principe, Joel Kidman, R. Lake, W. Lesterhuis, A. Nowak, A. McDonnell, Jonathan Chee · 2021 · Frontiers in Oncology
Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer
Mingjun Zheng, Junyu Long, Anca Chelariu-Raicu, Heather Mullikin, Theresa� Vilsmaier, Aurelia Vattai, Helene Hildegard Heidegger, Falk Batz, Simon Keckstein, Udo Jeschke et al. · 2021 · Cancers
Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
Sophia Stock, Anna-Kristina Kluever, Stefan Endres, Sebastian Kobold · 2022 · Biomedicines
Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model
Xuefeng Liu, Xiao‐Dong Zhu, Long-Hai Feng, Xiaolong Li, Bin Xu, Kangshuai Li, Nan Xiao, Ming Lei, Hui‐Chuan Sun, Zhao–You Tang · 2022 · Experimental Hematology and Oncology
Protein kinase Cι mediates immunosuppression in lung adenocarcinoma
Ning Yin, Yi Liu, Capella R. Weems, Barath Shreeder, Yanyan Lou, Keith L. Knutson, Nicole R. Murray, Alan P. Fields · 2022 · Science Translational Medicine
Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model
Khanidtha Chitphet, Sean M. Geary, Carlos H.F. Chan, Andrean L. Simons, George J. Weiner, Aliasger K. Salem · 2019 · ACS Biomaterials Science & Engineering
MST1/2: Important regulators of Hippo pathway in immune system associated diseases
Jingjing Zhou, Lanfang Li, Baojin Wu, Zhen Feng, Ying Lu, Zuoyun Wang · 2024 · Cancer Letters
Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer
Lin, Yu‐Chuan, Chen, Mei‐Chih, Huang, Shi‐Wei, Chen, Yeh, Ho, Jennifer Hui‐Chun, Lin, Fang‐Yu, Tan, Xiao‐Tong, Chiang, Hung‐Che, Huang, Chiu‐Ching, Tu, Chih‑Yen et al. · 2024 · Advanced Science
The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure
Shoulian Huang, Yu Kang, Ting Liu, Yan Xiong, Zixuan Yang, Qing Zhang · 2025 · Frontiers in Immunology
Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles
Moira C. Graves, Giovana Cellimarchett, Belinda van Zyl, Denise Tang, Ricardo E. Vilain, André van der Westhuizen, Nikola A. Bowden · 2019 · Frontiers in Medicine
Significance of TIM-3 Expression in Resected Esophageal Squamous Cell Carcinoma
Yuhuan Zhao, Donglai Chen, Wenjia Wang, Ting Zhao, Junmiao Wen, Fuquan Zhang, Shanzhou Duan, Chang Chen, Yonghua Sang, Yongsheng Zhang et al. · 2020 · The Annals of Thoracic Surgery
Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants
Reem Saleh, Salman M. Toor, Dana Al‐Ali, Varun Sasidharan Nair, Eyad Elkord · 2020 · Genes
Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy
Qingsheng Li, Phuong Ngo, Nejat K. Egilmez · 2020 · Cancer Immunology Immunotherapy
Combinations using checkpoint blockade to overcome resistance
Stefania Morganti, Giuseppe Curigliano · 2020 · ecancermedicalscience
Enhanced Immunotherapeutic Efficacy of Anti–PD-L1 Antibody in Combination with an EP4 Antagonist
Yamato Sajiki, Satoru Konnai, Zimeng Cai, Kensuke Takada, Tomohiro Okagawa, Naoya Maekawa, Sotaro Fujisawa, Yukinari Kato, Yasuhiko Suzuki, Shiro Murata et al. · 2020 · ImmunoHorizons
Resistance mechanisms to checkpoint inhibitors
Sarah Ann Weiss, Mario Sznol · 2021 · Current Opinion in Immunology
The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy
Reza Bayat Mokhtari, Manpreet Sambi, Bessi Qorri, Narges Baluch, Neda Ashayeri, Sushil Kumar, Hai‐Ling Margaret Cheng, Herman Yeger, Bikul Das, Myron R. Szewczuk · 2021 · Cancers
Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1
Víctor Cervera-Carrascón, Dafne C.A. Quixabeira, João Manuel Santos, Riikka Havunen, Ioanna E. Milenova, Jan Verhoeff, Camilla Heiniö, Sadia Zafar, Juan Jesús García-Vallejo, Victor W. van Beusechem et al. · 2021 · Frontiers in Immunology
Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications
Li-Shu Zhao, Hao Wang, Kan-Di Xu, Xinyue Liu, Ya-Yi He · 2022 · Chinese Medical Journal
Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma
Nonkululeko Z. Malinga, Shalete C. Siwele, Helen C. Steel, Luyanda L. I. Kwofie, Pieter W. A. Meyer, Teresa Smit, Ronald Anderson, Bernardo Leon Rapoport, Mahlatse Kgokolo · 2022 · Translational Oncology
Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents
Amir Iravani, Rodney J. Hicks · 2020 · Journal of Nuclear Medicine
Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model
Azizur M Rahman, Branislava Janic, Tasnim Rahman, Harshit Singh, Haythem Y. Ali, Ramandeep Rattan, Mohsin Kazi, Meser M. Ali · 2023 · Cancers
Recent advances in neoantigen vaccines for treating non‐small cell lung cancer
Shu Su, Fungjun Chen, Mingyuan Xu, Baorui Liu, Lifeng Wang · 2023 · Thoracic Cancer
Spatial features of specific CD103+CD8+ tissue-resident memory T cell subsets define the prognosis in patients with non-small cell lung cancer
Guanqun Yang, Siqi Cai, Mengyu Hu, Chaozhuo Li, Liying Yang, Wei Zhang, Jujie Sun, Fenghao Sun, Ligang Xing, Xiaorong Sun · 2024 · Journal of Translational Medicine
Toward innovative combinational immunotherapy: A systems biology perspective
Xuetao Li, Jin‐Ji Yang, Yi-Long Lung Cancer Wu, Jun Hou · 2018 · Cancer Treatment Reviews
Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression
Jesse D. Armitage, Hannah V. Newnes, Alison M. McDonnell, Anthony Bosco, Jason C. Waithman · 2021 · Cells
Immune checkpoint blockade in hematological malignancies: current state and future potential
Prateek A. Pophali, Juan Carlos Varela, Jacalyn M. Rosenblatt · 2024 · Frontiers in Oncology
Molecular insight into T cell exhaustion in hepatocellular carcinoma
Yonghua Zhu, Huabing Tan, Jincheng Wang, Haiwen Zhuang, Huanbin Zhao, Xiaojie Lu · 2024 · Pharmacological Research
Optical functional nanomaterials for cancer photoimmunotherapy
Longcai Liu, Yi Pan, Luyi Ye, Chen Liang, Xiaozhou Mou, Xiaochen Dong, Yu Cai · 2024 · Coordination Chemistry Reviews
Immunity‐Modulating Metal‐Based Nanomaterials for Cancer Immunotherapy
Xing Sun, Xican Xu, Fengying Li, Hongyu Wang, Yun Sun, Haokun Yang, Xiaoxu Li, Bo Kong, Hongwei Hou, Huiyu Liu et al. · 2025 · Advanced Functional Materials
Acquired resistance to immunotherapy in solid tumors
Perrine Verdys, Astrid Zedlitz Johansen, Anurag Kumar Gupta, Mario Presti, Edoardo Dionisio, Daniel Hargbøll Madsen, Alessandra Curioni Fontecedro, Marco Donia · 2025 · Trends in Molecular Medicine
Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients
Weili Wang, Kuansong Wang, Zihua Chen, Ling Chen, Wei Guo, Ping Liao, Daniel Miller Rotroff, Todd Cory Knepper, Zhaoqian Liu, Wei Zhang et al. · 2018 · Oncotarget
The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018
Olav Dahl, Marianne Brydøy · 2019 · Acta Oncologica
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
Sarah Elizabeth Fenton, Jeffrey Alan Sosman, Sunandana Chandra · 2019 · Cancer Drug Resistance
Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma
Alireza Isazadeh, Saba Hajazimian, Hamid Garshasbi, Behrouz Shadman, Amir Baghbanzadeh, Reza Chavoshi, Sina Taefehshokr, Mahdieh Farhoudi Sefidan Jadid, Khalil Hajiasgharzadeh, Behzad Baradaran · 2020 · Journal of Cellular Physiology
An Antigen‐Delivery Protein Nanoparticle Combined with Anti‐PD‐1 Checkpoint Inhibitor Has Curative Efficacy in an Aggressive Melanoma Model
Medea Neek, Jo Anne Tucker, Nina Butkovich, Edward L. Nelson, Szu‐Wen Wang · 2020 · Advanced Therapeutics
Anticancer natural products targeting immune checkpoint protein network
Kyung‐Soo Chun, Do‐Hee Kim, Pawan Kumar Raut, Young‐Joon Surh · 2021 · Seminars in Cancer Biology
Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma
Kaidi Yang, Yu Shi, Min Luo, Min Mao, Xiaoning Zhang, Cong Chen, Yuqi Liu, Zhicheng He, Qing Liu, Wenying Wang et al. · 2022 · OncoImmunology
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy
Andrea Botticelli, Giulia Pomati, Alessio Cirillo, Simone Scagnoli, Simona Pisegna, Antonella Chiavassa, Ernesto Rossi, Giovanni Schinzari, Giampaolo Tortora, Francesca Romana Di Pietro et al. · 2022 · Frontiers in Immunology
The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma
Xudong Liu, Wufei Dai, Zihui Zhao, Kuo Liao, Qi Sun, Dongjiang Chen, Xingxin Pan, Lishuang Feng, Ying Ding, Shiyou Wei · 2023 · Cancers
Dawning precision treatment for gastric cancer: The latest biomarkers
Keran Sun, Huifang Lv, Beibei Chen, Caiyun Nie, Jing Zhao, Saiqi Wang, Jianzheng Wang, Weifeng Xu, Xiaobing Chen · 2021 · Journal of Translational Internal Medicine
Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade
Felipe I. Espinoza, Stoyan Tankov, Sylvie Chliate, Joana Pereira Couto, Eliana Marinari, Thibaud Vermeil, Marc Lecoultre, Nadia El Harane, Valérie Dutoit, Denis Migliorini et al. · 2025 · Cellular and Molecular Life Sciences
First-in-human phase I open-label study of the anti–TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors
Martin E Gutierrez, Shou‐Ching Tang, John D. Powderly, Ani Sarkis Balmanoukian, Paul Hoyle, Zhiwan Dong, Lulu L Cheng, Xiaohua Gong, John Edward Janik, Nawel Bourayou et al. · 2025 · The Oncologist
T Cells Deficient in Diacylglycerol Kinase ζ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia
Weiqing Jing, Jill A. Gershan, Sandra Holzhauer, James J. Weber, Katie A. Palen, Laura McOlash, Kirthi Pulakanti, Erin Wesley, Sridhar Rao, Bryon D. Johnson et al. · 2017 · Cancer Research
Cancer immune resistance: can theories converge?
Rongze Olivia. Lu, Tolga Turan, Josue A. Samayoa, Francesco Maria Marincola · 2017 · Emerging Topics in Life Sciences
Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?
Purushottam Lamichhane, N. Amin, M. Agarwal, N. Lamichhane · 2018 · Medicines
Rational combination of cancer immunotherapy in melanoma
Mario Mandalà, Piotr Lukasz Rutkowski · 2018 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment
Isacco Ferrarini, Antonella Rigo, Carlo Visco, Mauro Krampera, Fabrizio Vinante · 2020 · Cancers
Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events
Yanlin Zeng, Qingya Shi, Xinyu Liu, Hao Thi Tang, Bo Lu, Qingyang Zhou, Yan Xu, Minjiang Chen, Jing Zhao, Yue Li et al. · 2023 · Frontiers in Oncology
Immunotherapy in Melanoma: Recent Advancements and Future Directions
Meghan J. Mooradian, Ryan Joseph Sullivan · 2023 · Cancers
Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia
Shuxin Huang, Yujie Zhao, Wenpu Lai, Jiaxiong Tan, Xue Zheng, Xianfeng Zha, Yangqiu Li, Shaohua Chen · 2023 · Cancer Biology & Therapy
The challenges of checkpoint inhibition in the treatment of multiple myeloma
Barry A. Paul, Shuqi Kang, Zhihong Zheng, Yubin Kang · 2018 · Cellular Immunology
Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma
Barbara Castella, Assunta Melaccio, Myriam Foglietta, Chiara Riganti, Massimo Massaia · 2018 · Frontiers in Oncology
A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
Erica T. Goddard, Jacob Fischer, Pepper S. Schedin · 2016 · Journal of Visualized Experiments
Galectin-9 and Tim-3 in gastric cancer: a checkpoint axis driving T cell exhaustion and Treg-mediated immunosuppression independently of anti-PD-1 blockade
Charlotte Nicole Hill, Gabriela Maita, Camille Cabrolier, Constanza Aros, Ana María Vega-Letter, Pamela González, Alexis M. Kalergis, Patricia Luz‐Crawford, Gareth I. Owen · 2025 · Frontiers in Immunology
Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.
Zuyuan Lin, Di Lu, Xuyong Wei, Jianguo Wang, Xiao Xu · 2020 · PubMed Central
Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma
Andy Karabajakian, Thibaut Garrivier, Carole Crozes, Nicolas Gadot, Jean‐Yves Blay, F. Bérard, Philippe Céruse, Philippe Zrounba, Pierre Saintigny, Charles Mastier et al. · 2020 · Oncotarget
Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview
João Calmeiro, Mylène A. Carrascal, Adriana Ramos Tavares, Daniel Alexandre Ferreira, Célia M. F. Gomes, Maria Teresa Cruz, Amílcar C. Falcão, Bruno Miguel Neves · 2020 · Pharmacological Research
Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
Xiaoqiang Yin, Tongchui Wu, Yadong Lan, Wulin Yang · 2022 · Bioscience Reports
Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer
S Anupriya, Averi Chakraborty, Srinivas Patnaik · 2022 · Mutation Research/Reviews in Mutation Research
New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review)
Yanjun Wang, Shuo Yang, Li Wan, Wei Ling, Hao Hui Chen, Jinghua Wang · 2023 · International Journal of Oncology
Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?
Peter Kok-Ting Wan, Ricardo A. Fernandes, Leonard William Seymour · 2023 · Journal for ImmunoTherapy of Cancer
Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications
Janna Krueger, Christopher E. Rudd, Alison Taylor · 2019 · Seminars in Immunology
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies
Josée Golay, Alain E. Andrea · 2020 · Antibodies
Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18–12
Ji Hyun Park, Sang Hoon Chun, Yun‐Gyoo Lee, Hyun Kyung Chang, Keun‐Wook Lee, Hye Ryun Kim, Seong Hoon Shin, Ho Jung An, Kyoung Eun Lee, In Gyu Hwang et al. · 2020 · Journal of Cancer Research and Clinical Oncology
Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook
Patrick C. Gedeon, Cosette D. Champion, Kristen Elizabeth Rhodin, Karolina I. Woroniecka, Hanna R. Kemeny, Alexa N. Bramall, Joshua D. Bernstock, Bryan D. Choi, John Howard Sampson · 2020 · Expert Review of Clinical Pharmacology